Back to mobile site

JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)

November 5, 2024 2:56 PM EST Send to a Friend
JPMorgan analyst Eric Joseph reiterated an Overweight rating and $48.00 price target on Beam ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login